%0 Journal Article
%T Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss.
%A Modestino EJ
%A Bowirrat A
%A Lewandrowski KU
%A Sharafshah A
%A Badgaiyan RD
%A Thanos PK
%A Baron D
%A Dennen CA
%A Elman I
%A Sunder K
%A Murphy KT
%A Blum K
%J Acta Sci Neurol
%V 7
%N 5
%D 2024 May
%M 39118673
暂无%R 10.31080/asne.2024.07.0731
%X The widespread adoption of Glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of obesity and diabetes has raised concerns about their potential adverse effects, including the induction of depression and suicide ideation. We report on a male patient in his early 50s with a complex medical history, including adult Attention-Deficit/Hyperactive Disorder, narcolepsy with cataplexy, and major depressive disorder in remission, who experienced exacerbated hemiplegic migraines after initiating treatment with an injectable GLP-1 agonist (Saxenda) for weight loss. Despite a previous history of experiencing hemiplegic migraines once or twice a year, the patient reported daily occurrences of migraines, many of which were hemiplegic, during the 60 days of GLP-1 agonist treatment. The migraines abated only upon discontinuation of the medication. This case underscores the need to carefully consider patient history and potential genetic predispositions when prescribing GLP-1 agonists, highlighting the complex interactions between these medications, existing comorbidities, and the dopaminergic and calcitonin gene-related peptide pathways. Our findings suggest that GLP-1 agonists, while beneficial for some, may pose significant risks for patients with specific genetic backgrounds or neurological conditions, calling for personalized approaches to treatment and increased awareness of potential adverse effects.